Principal Scientist
Alnylam Pharmaceuticals
Principal Scientist
Alnylam Pharmaceuticals
Develops RNAi-based therapies for genetic diseases
Overview:
We are seeking an experienced and highly motivated Principal Scientist, Biotransformation & Metabolite Profiling to provide scientific leadership in the characterization of drug metabolism and biotransformation across discovery and development programs.
The successful candidate will develop and execute integrated metabolite profiling and identification strategies using state-of-the-art LC-HRMS/MS approaches. The role will support a range of therapeutic modalities, including small molecules, peptides, RNAi, conjugated therapeutics, and other emerging modalities.
The scientist will serve as a subject-matter expert in metabolite identification and biotransformation, partnering closely with DMPK, bioanalytical sciences, pharmacology, toxicology, research/biology, and other project functions to translate metabolite data into actionable understanding of drug disposition, efficacy, and safety.
Key Responsibilities:
Qualifications:
About Alnylam
We are the leader in RNAi therapeutics – a revolutionary approach with the potential to transform the lives of people with rare and common diseases. Built on Nobel Prize-winning science, Alnylam has delivered the breakthroughs that made RNAi therapeutics possible and are just at the beginning of what’s possible. Our deep pipeline, late-stage programs, and bold vision reflect our core values: fierce innovation, passion for excellence, purposeful urgency, open culture and commitment to people. We're proud to be a globally recognized top employer, where an authentic, inclusive culture and breakthrough thinking fuel one another.
At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. Qualified applicants will receive consideration for employment without regard to their sex, gender or gender identity, sexual orientation, race, color, ethnicity, national origin, ancestry, citizenship, religion, creed, physical or mental disability, pregnancy status or related conditions, genetic information, veteran or military status, marital or familial status, political affiliation, age, or any other factor protected by federal, state, or local law. Alnylam is an E-Verify Employer.
Before applying, please review Alnylam's Candidate Privacy Notice regarding how Alnylam handles Personal Data you provide with your application for employment.
#LI-JRI
#LI-Onsite
Develops RNAi-based therapies for genetic diseases
Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.
Explore more opportunities at Alnylam Pharmaceuticals